Stock ABLI ABLIVA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 03:14:04 2024-06-04 am EDT 		5-day change 1st Jan Change
0.1798 SEK +2.74% Intraday chart for Abliva AB -1.86% -26.76%
May. 30 Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug MT
May. 30 Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 249.2 226.7 240.8 189.1 259.3 236.1 - -
Enterprise Value (EV) 1 190.9 226.7 218.5 189.1 259.3 214.1 154.1 236.1
P/E ratio -2.98 x -3.19 x -1.81 x -1.49 x -2.73 x -1.75 x -1.46 x -1.75 x
Yield - - - - - - - -
Capitalization / Revenue 1,860 x 122 x 1,595 x - - - - 78.7 x
EV / Revenue 1,424 x 122 x 1,447 x - - - - 78.7 x
EV / EBITDA -2.56 x -3.94 x -1.81 x - - -1.71 x -1.08 x -1.5 x
EV / FCF - - - - - -1.78 x -1.1 x -
FCF Yield - - - - - -56% -90.8% -
Price to Book - - - - - 1.46 x - -
Nbr of stocks (in thousands) 185,953 296,340 403,007 1,056,299 1,056,299 1,349,385 - -
Reference price 2 1.340 0.7650 0.5975 0.1790 0.2455 0.1750 0.1750 0.1750
Announcement Date 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.134 1.864 0.151 - - - - 3
EBITDA 1 -74.7 -57.51 -120.7 - - -125 -143 -157
EBIT 1 -77.07 -60.07 -123.5 - - -128 -146 -161
Operating Margin -57,517.91% -3,222.69% -81,776.16% - - - - -5,366.67%
Earnings before Tax (EBT) 1 -77 -59.99 -123.5 - - -128 -146 -
Net income 1 -76.99 -59.99 -123.5 -85.26 -95.51 -128 -146 -
Net margin -57,458.21% -3,218.56% -81,786.75% - - - - -
EPS 2 -0.4500 -0.2400 -0.3300 -0.1200 -0.0900 -0.1000 -0.1200 -0.1000
Free Cash Flow 1 - - - - - -120 -140 -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 58.3 - 22.3 - - 22 82 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -120 -140 -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - - - 0.1200 - -
Cash Flow per Share - - - - - - - -
Capex 1 0.07 - - - - 1 1 -
Capex / Sales 51.49% - - - - - - -
Announcement Date 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABLIVA AB Stock Abliva AB
-26.76% 22.67M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.55% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.66% 107B
BIONTECH SE Stock BioNTech SE
-2.53% 24.82B
ARGENX SE Stock argenx SE
+1.14% 22.48B
GENMAB A/S Stock Genmab A/S
-9.19% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.92% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.19% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.83% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABLI Stock
  4. Financials Abliva AB